Your Manufacturing Licence Is Being Delayed by an Inspection the Law Says You Don't Need
The Class A Manufacturing Licence You Can Get in 45 Days — Without a Single Site Audit
By Ankur Khare — Biomedical Engineer | Regulatory Affairs Specialist | Founder, MedReg Intel
India's medical device manufacturing landscape has a problem that is entirely of its own making.
Not a regulatory problem. Not a policy problem. A knowledge problem.
Thousands of Indian MedTech startups and small manufacturers are waiting months — sometimes close to a year — for manufacturing licences they could have in 45 days. They are waiting for inspections that the law says are not required before the licence is granted. They are delaying product launches, burning investor runway, and losing market windows because nobody told them what Rule 20(4) of MDR 2017 actually says.
This article tells them.
What Most People Believe About Manufacturing Licences
The standard narrative in Indian MedTech goes like this.
You apply for a manufacturing licence. CDSCO or your State Licensing Authority schedules an inspection of your manufacturing site. The inspection happens — eventually. The inspection report is prepared and submitted. The authority reviews the report. Then and only then is your licence granted.
This narrative is partially correct. For Class C and Class D devices it is largely accurate. For Class B devices it is accurate with specific timelines.
For Class A devices it is wrong.
And Class A covers a significant and commercially important range of medical devices — non-invasive devices, basic wound care products, non-sterile examination gloves, many diagnostic accessories, hospital furniture, mobility aids, and a substantial portion of the devices that Indian MedTech startups are actually building.
What Rule 20(4) Actually Says
Rule 20(4) of MDR 2017 states that the State Licensing Authority shall grant a licence to manufacture Class A medical devices in Form MD-5 or reject the application for reasons to be recorded in writing within forty five days from the date the application is made.
That is the mandatory decision timeline. Forty five days from application date.
But the critical provision is in the proviso immediately following. Rule 20(4) proviso clause (i) states verbatim:
"no audit of the manufacturing site shall be necessary prior to grant of licence or loan licence to manufacture for sale or for distribution of Class A medical device."
Read that again.
No audit of the manufacturing site shall be necessary prior to grant of licence.
The pre-grant site inspection that most manufacturers assume is blocking their licence — for Class A devices it does not exist. The law explicitly removes it as a precondition.
A complete application submitted to the State Licensing Authority. Forty five days. A valid Class A manufacturing licence in Form MD-5. No inspection required before that licence is in your hands.
Where the Audit Actually Happens
The Notified Body audit for Class A devices does happen. It is not eliminated — it is repositioned.
Rule 20(4) proviso clause (ii) states that the required audit of the manufacturing site by a registered Notified Body shall be carried out within one hundred and twenty days from the date on which the licence was granted.
The audit happens after the licence. Not before it.
This is a fundamental structural difference from what most manufacturers are told. The sequence is not apply, wait for inspection, get licence. The sequence is apply, get licence in 45 days, prepare for Notified Body audit in the following 120 days.
During those 120 days after licence grant your manufacturing licence is valid. You can manufacture. You can sell. You can generate revenue. You can build your commercial relationships while simultaneously preparing for the Notified Body audit that will happen post-grant.
The Notified Body audit is not a threat to your operations — it is a quality verification that happens while your business is already running.
The Deemed Approval Safety Net
The 45 day timeline is not just a target. It is a statutory obligation on the State Licensing Authority.
If the SLA does not grant the licence or reject the application with recorded reasons within 45 days of a complete application — what happens?
Read Rule 20(4) in conjunction with the broader deemed approval architecture of MDR 2017. A State Licensing Authority that fails to communicate within the statutory period has not met its legal obligation. The application and the statutory timeline create a basis for formal escalation and appeal under Rule 20(7).
The practical implication is this. Track your application submission date precisely. At day 35 send a formal written follow-up to the SLA citing the application reference, the submission date, and Rule 20(4)'s 45 day mandate. If day 45 passes without communication, escalate formally citing the statutory timeline. Do not wait indefinitely. The law gives the authority 45 days. After that the inaction is the authority's failure, not your problem to absorb silently.
The Class B Distinction — Know the Difference
Class A and Class B are both handled by the State Licensing Authority under Rule 20. But the licence grant process is structurally different for Class B.
For Class B devices the Notified Body audit happens before licence grant — not after.
Rule 20(6) sets out the sequence. The Notified Body audit must be carried out within 90 days from the date of application. The Notified Body furnishes its report to the SLA within 30 days of completing the audit. The SLA then has 20 days from receipt of the audit report to grant or reject the licence.
Total realistic timeline for Class B: 90 days for audit plus 30 days for report plus 20 days for SLA decision. Approximately 140 days from application under the statutory framework — longer in practice if Notified Body scheduling is delayed.
The contrast with Class A is significant. Class A — 45 days, no pre-grant audit. Class B — approximately 140 days, pre-grant audit required.
If your device classification sits at the boundary between Class A and Class B — and many do — understanding this timeline difference is a material commercial consideration. A well-argued classification at Class A rather than Class B is not just a regulatory position. It is a market entry timeline decision worth months of runway.
The Loan Licence Route for Startups Without a Facility
Rule 20 also provides a pathway that is underused by Indian MedTech startups — the loan licence.
A loan licence under Rule 3(z) is a licence issued to a person who intends to utilise the manufacturing site of another licensee for manufacturing the same medical device as manufactured by that licensee at that site.
The practical implication is this. A startup that has developed a Class A device but does not yet have its own manufacturing facility can apply for a loan licence to manufacture at an already licensed facility. The application process follows the same Rule 20 framework. The same 45 day timeline applies. The same no-pre-grant-audit provision applies for Class A.
This means a startup with a product and a manufacturing partner but no owned facility can have a valid loan licence to manufacture and sell within 45 days — without building or leasing a manufacturing site, without investing in facility compliance from scratch, and without waiting for a pre-grant inspection that does not exist for Class A.
The loan licence route dramatically reduces the capital requirement for market entry for Class A device startups. It is not a shortcut — the manufacturing site must already be licensed and compliant. But it is a legitimate, explicitly provided pathway that most startup founders and their advisors do not know exists.
What a Complete Application Actually Requires
The 45 day clock starts from the date of a complete application. An incomplete application does not trigger the timeline properly — and gives the SLA grounds to reject or issue deficiency notices that reset the clock.
Rule 20(2) specifies that the application in Form MD-3 for licence or Form MD-4 for loan licence must be accompanied by a fee as specified in the Second Schedule along with documents as specified in Part II of the Fourth Schedule.
Rule 20(3) requires the application to be accompanied by an undertaking that the requirements of the Quality Management System as specified in the Fifth Schedule have been complied with.
The QMS undertaking is important. For Class A devices no pre-grant audit verifies the QMS — but the undertaking is a legal declaration. The post-grant Notified Body audit will verify whether the QMS actually meets Fifth Schedule requirements. A manufacturer who submits the undertaking without having a functioning QMS is creating a post-grant compliance problem that can result in licence suspension.
The 45 day pathway is real and legitimate. It works when the application is complete and the QMS is genuinely in place — not when the undertaking is filed as a formality and the QMS exists only on paper.
The Quality Management System — What to Have Ready
Since the Notified Body audit happens within 120 days of licence grant, a Class A manufacturer has a defined window to have their QMS audit-ready.
The Fifth Schedule QMS requirements for medical device manufacturers align broadly with ISO 13485 — the international quality management standard for medical devices. A manufacturer who has implemented or is implementing ISO 13485 is building the foundation that the Notified Body audit will assess.
The 120 day post-grant window is not a holiday. It is the preparation period for the Notified Body audit that will determine whether the licence remains valid. A manufacturer who uses those 120 days well — documenting procedures, training staff, completing internal audits, preparing the technical file — will pass the Notified Body audit and retain the licence.
A manufacturer who ignores the 120 day window and treats licence grant as the finish line will face a Notified Body finding of major non-compliance and potential licence consequences.
The strategic use of the 45 day licence pathway is get to market fast and use the commercial momentum of the first 120 days to fund and accelerate QMS completion simultaneously.
What This Means for Indian MedTech Startups
The 45 day Class A manufacturing licence provision changes the market entry calculus for Indian MedTech startups in three specific ways.
First it changes the fundraising conversation. A startup that can demonstrate a valid manufacturing licence within 45 days of completing its application has a materially different investor story than one projecting 9 to 12 months for regulatory clearance. Regulatory timeline is one of the most significant risk factors investors assess in MedTech. Compressing it with a provision-backed argument is a genuine de-risking of the investment thesis.
Second it changes the competitive dynamics. The manufacturers currently selling in Class A categories are not facing a regulatory moat of multiple years. The regulatory pathway is 45 days for a complete application. The real competitive moat is product quality, clinical relationships, and distribution — not regulatory timeline. A startup that moves quickly through the 45 day pathway and builds those commercial advantages early is ahead of a competitor that spent 12 months waiting for an inspection that the law never required.
Third it changes the burn rate calculation. Every month of pre-revenue delay costs a startup its runway. A manufacturing licence in 45 days versus 9 months is potentially 8 months of additional runway preserved — without raising a single additional rupee. That is the most capital-efficient regulatory strategy available to a Class A device manufacturer.
The Bottom Line
Rule 20(4) of MDR 2017 and its proviso are explicit.
Class A manufacturing licence — 45 days from complete application. No pre-grant site audit required. Post-grant Notified Body audit within 120 days.
Class A loan licence — same timeline, same no pre-grant audit provision, for startups manufacturing at an existing licensed facility.
The manufacturers currently waiting 9 to 12 months for Class A manufacturing licences are not waiting because the law requires it. They are waiting because nobody told them it does not.
That is a solvable problem.
MedReg Intel tracks regulatory developments, compliance strategy, and policy analysis relevant to India's medical device sector at medregintel.com
If you are a Class A device manufacturer or MedTech startup evaluating your manufacturing licence pathway — or have an application pending with your State Licensing Authority — reach out at ankur@medregintel.com for a regulatory pathway assessment.
Ankur Khare is a Biomedical Engineer and Regulatory Affairs Specialist and the founder of MedReg Intel. This article is for informational purposes and does not constitute formal regulatory or legal advice.
Comments
Post a Comment